Hubei Huazhong Pharmaceutical Co. Ltd.

Sitagliptin metformin extended-release tablets (100 mg/1000 mg) produced by Huazhong Pharmaceutical Co., Ltd. were used as the test preparation, and sitagliptin metformin extended-release tablets (Janumet Xr®, 100 mg/1000 mg) marketed by Merck Sharp and Dohme Corp. were used as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two preparations after single administration in the fasting and postprandial states were investigated to evaluate whether the two preparations were bioequivalent, and the safety of the two preparations in healthy subjects was evaluated.

To investigate whether there are differences in the extent and rate of absorption of the test preparation Enteric-coated Aspirin Tablets (Huazhong Pharmaceutical Co., Ltd., specification: 100 mg) and the reference preparation Enteric-coated Aspirin Tablets (trade name: Bayaspirin®; Bayer S.p.A., specification: 100 mg) when taken orally on an empty stomach or after a meal in healthy subjects, to evaluate the bioequivalence of the test preparation and the reference preparation when administered on an empty stomach or after a meal, and to observe the safety of the test preparation and the reference preparation in healthy subjects.

To investigate whether there are differences in the extent and rate of absorption between the test preparation sacubitril-valsartan sodium tablets (Huazhong Pharmaceutical Co., Ltd., specification: 50 mg, sacubitril/valsartan (24 mg/26 mg)) and the reference preparation sacubitril-valsartan sodium tablets (trade name: Nusintuo®, Novartis Pharma Schweiz AG, specification: 50 mg, sacubitril/valsartan (24 mg/26 mg)) after a single oral administration on an empty stomach in healthy subjects, to evaluate the bioequivalence of the test preparation and the reference preparation when administered in the fasting state, and to observe the safety of the test preparation and the reference preparation in healthy subjects.